Tag: Relapsed pediatric LGG therapy

Home / Relapsed pediatric LGG therapy

Categories

Tovorafenib has been granted accelerated approval by the FDA for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma

April 2024: The Food and Drug Administration (FDA) granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.). This approval is specifically for patients aged 6 months and ...
relapsed-pediatric-lgg-therapy

Scan the code